Patents Assigned to Merck Frosst Canada, Inc.
  • Patent number: 5789413
    Abstract: The invention encompasses the novel compound of Formula I useful in the treatment of cyclooxygenase-2 mediated diseases. ##STR1## The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of Formula I.
    Type: Grant
    Filed: January 21, 1997
    Date of Patent: August 4, 1998
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Cameron Black, Erich Grimm, Serge Leger, Greg Hughes, Petpiboon Prasit, Zhaoyin Wang
  • Patent number: 5767291
    Abstract: The invention encompasses the novel compound of Formula I useful in the treatment of cyclooxygenase-2 mediated diseases. ##STR1## The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of Formula I.
    Type: Grant
    Filed: October 25, 1996
    Date of Patent: June 16, 1998
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Yves Ducharme, Jacques Yves Gauthier, Petpiboon Prasit, Yves Leblanc, Zhaoyin Wang, Serge Leger, Michel Therien
  • Patent number: 5760180
    Abstract: A complementary DNA (cDNA) encoding full length form of ICE.sub.rel -III is identified, sequenced and isolated. The cDNA is cloned into expression vectors for expression in recombinant hosts. The cDNA is useful to produce recombinant full length ICE.sub.rel -III. The cDNA and the recombinant ICE.sub.rel -III protein derived therefrom are useful in diagnostic kits, laboratory reagents and assays. The cDNA and the recombinant ICE.sub.rel -III protein may be used to identify compounds that affect ICE.sub.rel -III function, inflammation and cell apoptosis. ICE.sub.rel -III function, inflammation and cell apoptosis may also be modulated by ICE.sub.rel -III antisense or gene therapy.
    Type: Grant
    Filed: December 9, 1996
    Date of Patent: June 2, 1998
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Donald W. Nicholson, Ambereen Ali, Neil A. Munday, John P. Vaillancourt
  • Patent number: 5759789
    Abstract: A novel prostaglandin receptor has been identified and DNA encoding the receptor has been isolated, purified, sequenced and expressed in host cells. This DNA encoding the novel prostaglandin receptor and host cells expressing the receptor are used to identify modulators of the prostaglandin receptor.
    Type: Grant
    Filed: August 5, 1996
    Date of Patent: June 2, 1998
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Mark Abramovitz, Mohammed Adam, Lison Bastien, Richard Grygorczyk, Kathleen Metters, Thomas H. Ruchmore, Nicole Sawyer
  • Patent number: 5733909
    Abstract: The invention encompasses the novel compound of Formula I useful in the treatment of cyclooxygenase-2 mediated diseases. ##STR1## The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of Formula I.
    Type: Grant
    Filed: January 21, 1997
    Date of Patent: March 31, 1998
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Cameron Black, Mario Girard, Daniel Guay, Zhaoyin Wang
  • Patent number: 5728808
    Abstract: A novel prostaglandin receptor has been identified and DNA encoding the receptor has been isolated, purified, sequenced and expressed in host cells. This DNA encoding the novel prostaglandin receptor and host cells expressing the receptor are used to identify modulators of the prostaglandin receptor.
    Type: Grant
    Filed: August 29, 1995
    Date of Patent: March 17, 1998
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Mark Abramovitz, Yves Bole, Richard Grygorczyk, Kathleen Metters, Thomas H. Rushmore, Deborah M. Slipetz
  • Patent number: 5710140
    Abstract: The invention encompasses the novel compound of Formula I useful in the treatment of cyclooxygenase-2 mediated diseases. ##STR1## The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of Formula I.
    Type: Grant
    Filed: August 16, 1996
    Date of Patent: January 20, 1998
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Yves Ducharme, Jacques Yves Gauthier, Petpiboon Prasit, Yves Leblanc, Zhaoyin Wang, Serge Leger, Michel Therien
  • Patent number: 5710160
    Abstract: The invention encompasses the novel compound of Formula I useful in the treatment of diseases, including asthma, by raising the level of cyclic adenosine-3',5'-monophosphate (cAMP) through the inhibition of phosphodiesterase IV (PDE IV). ##STR1## The invention also encompasses certain pharmaceutical compositions and methods for treatment of diseases by inhibition of PDE IV, resulting in an elevation of cAMP, comprising the use of compounds of Formula I.
    Type: Grant
    Filed: December 10, 1996
    Date of Patent: January 20, 1998
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Daniel Guay, Yves Girard, Yves Ducharme
  • Patent number: 5710170
    Abstract: The invention encompasses the novel compound of Formula I useful in the treatment of diseases, including asthma, by raising the level of cyclic adenosine-3',5'-monophosphate (cAMP) through the inhibition of phosphodiesterase IV (PDE IV). ##STR1## The invention also encompasses certain pharmaceutical compositions and methods for treatment of diseases by inhibition of PDE IV, resulting in an elevation of cAMP, comprising the use of compounds of Formula I.
    Type: Grant
    Filed: December 10, 1996
    Date of Patent: January 20, 1998
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Daniel Guay, Yves Girard, Yves Ducharme, Marc Blouin, Pierre Hamel, Mario Girard
  • Patent number: 5698584
    Abstract: The invention encompasses the novel compound of Formula I useful in the treatment of cyclooxygenase-2 mediated diseases. ##STR1## The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of Formula I.
    Type: Grant
    Filed: October 25, 1996
    Date of Patent: December 16, 1997
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Cameron Black, Serge Leger, Petpiboon Prasit, Zhaoyin Wang, Pierre Hamel, Yongxin Han, Gregory Hughes
  • Patent number: 5691374
    Abstract: The invention encompasses the novel compound of Formula I as well as a method of treating cyclooxygenase-2 mediated diseases comprising administration to a patient in need of such treatment of a non-toxic therapeutically effective amount of a compound of Formula I. ##STR1## The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of Formula I.
    Type: Grant
    Filed: May 18, 1995
    Date of Patent: November 25, 1997
    Assignee: Merck Frosst Canada Inc.
    Inventors: Cameron Black, Erich Grimm, Zhaoyin Wang, Serge Leger
  • Patent number: 5681936
    Abstract: Disclosed is a method for purifying Human interleukin-5 (IL-5) a single chromatographic step. After removing cells from a cell culture expressing human interleukin-5, IL-5 is purified by first adjusting the culture supernatant to the calculated pI value of mature IL-5 (pI=7.44) and then passing the conditioned supernatant through tandem linked anion- and cation-exchange columns. The resulting pass-through fraction contains the IL-5 and is devoid of all other contaminating proteins. An optional hydrophobic-interaction chromatography step is disclosed for positive selection of IL-5 and in order to concentrate the preparation. Pure IL-5 was recovered with a high overall yield (>90%), was N-glycosylated and was entirely homodimeric.
    Type: Grant
    Filed: June 6, 1995
    Date of Patent: October 28, 1997
    Assignee: Merck Frosst Canada, Inc.
    Inventor: Donald Nicholson
  • Patent number: 5677318
    Abstract: The invention encompasses the novel compound of Formula I as well as a method of treating COX-2 mediated diseases comprising administration to a patient in need of such treatment of a non-toxic therapeutically effective amount of a compound of Formula I. ##STR1## The invention also encompasses certain pharmaceutical compositions for treatment of COX-2 mediated diseases comprising compounds of Formula I.
    Type: Grant
    Filed: July 11, 1996
    Date of Patent: October 14, 1997
    Assignee: Merck Frosst Canada, Inc.
    Inventor: Cheuk Kun Lau
  • Patent number: 5639780
    Abstract: The invention encompasses the novel compound of Formula I useful in the treatment of cyclooxygenase-2 mediated diseases. ##STR1## The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of Formula I.
    Type: Grant
    Filed: May 22, 1995
    Date of Patent: June 17, 1997
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Cheuk Kun Lau, Cameron Black, Daniel Guay, Jacques-Yves Gauthier, Yves LeBlanc, Patrick Roy, Yves Ducharme, Pierre Hamel
  • Patent number: 5605906
    Abstract: Disclosed are novel cannabinoid (CB2) receptor agonists, their compositions, and the methods of their preparation. The compounds are useful for lowering ocular intra ocular pressure, treating glaucoma, useful as antiinflammatory, immunosuppressive, analgesics agents, and as agents for treatment and prevention of emesis and nausea because of the activity on the cannabinoid receptor.
    Type: Grant
    Filed: March 24, 1995
    Date of Patent: February 25, 1997
    Assignee: Merck Frosst Canada, Inc.
    Inventor: Cheuk K. Lau
  • Patent number: 5605814
    Abstract: A novel prostaglandin receptor has been identified and DNA encoding the receptor has been isolated, purified, sequenced and expressed in host cells. This DNA encoding the novel prostaglandin receptor and host cells expressing the receptor are used to identify modulators of the prostaglandin receptor.
    Type: Grant
    Filed: August 31, 1993
    Date of Patent: February 25, 1997
    Assignee: Merck Frosst Canada Inc.
    Inventors: Mark Abramovitz, Mohammed Adam, Lison Bastien, Richard Grygorczyk, Kathleen Metters, Thomas H. Rushmore, Nicole Sawyer
  • Patent number: 5604260
    Abstract: The Compound of Formula I and pharmaceutically acceptable salts thereof in the treatment of cyclooxygenase-2 mediated diseases are disclosed.
    Type: Grant
    Filed: November 4, 1993
    Date of Patent: February 18, 1997
    Assignee: Merck Frosst Canada Inc.
    Inventors: Daniel Guay, Chun-Sing Li
  • Patent number: 5604253
    Abstract: The invention encompasses the novel compound of Formula I as well as a method of treating cyclooxygenase-2 mediated diseases comprising administration to a patient in need of such treatment of a non-toxic therapeutically effective amount of a compound of Formula I. ##STR1## The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of Formula I.
    Type: Grant
    Filed: May 22, 1995
    Date of Patent: February 18, 1997
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Cheuk K. Lau, Cameron Black, Daniel Guay, Jacques Y. Gauthier, Yves LeBlanc, Patrick Roy, Yves Ducharme, Pierre Hamel
  • Patent number: 5601801
    Abstract: Angiotensin convening enzyme (ACE) inhibitors can be labelled with Iodine-123, Iodine-125, Iodine-127 or Iodine-131, useful to image the kidneys and lungs for diagnosis and treatment of diseases such as essential hypertension, renal artery stenosis, or diabetes which are associated with a change in the amount of ACE present in the human body.
    Type: Grant
    Filed: August 2, 1994
    Date of Patent: February 11, 1997
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Richard J. Flanagan, Duncan H. Hunter, Vincenzo Quiquero, Pamela Zabel
  • Patent number: 5576338
    Abstract: Compounds having the Formula I: ##STR1## are inhibitors of leukotriene biosynthesis. These compounds are useful as anti-asthmatic, anti-allergic, anti-inflammatory, and cytoprotective agents. They are also useful in treating angina, cerebral spasm, glomerular nephritis, hepatitis, endotoxemia, uveitis, and allograft rejection and in preventing the formation of atherosclerotic plaques.
    Type: Grant
    Filed: February 15, 1995
    Date of Patent: November 19, 1996
    Assignee: Merck Frosst Canada, Inc.
    Inventors: Richard Friesen, Yves Ducharme, Daniel Dube', Carole Lepine, Daniel Delorme, Pierre Hamel